Cargando…
Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition
BACKGROUND: Plasma β-amyloid (Aβ) is a potential candidate for an Alzheimer’s disease (AD) biomarker because blood is an easily accessible bio-fluid, which can be collected routinely, and Aβ is one of the major hallmarks of AD pathogenesis in the brain. However, the association between plasma Aβ lev...
Autores principales: | Park, Jong-Chan, Han, Sun-Ho, Cho, Hyun Jin, Byun, Min Soo, Yi, Dahyun, Choe, Young Min, Kang, Seokjo, Jung, Eun Sun, Won, Su Jin, Kim, Eun Hye, Kim, Yu Kyeong, Lee, Dong Young, Mook-Jung, Inhee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361707/ https://www.ncbi.nlm.nih.gov/pubmed/28330509 http://dx.doi.org/10.1186/s13195-017-0248-8 |
Ejemplares similares
-
Performance of the QPLEX™ Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition
por: Park, Jong-Chan, et al.
Publicado: (2021) -
Application of QPLEX(TM) biomarkers in cognitively normal individuals across a broad age range and diverse regions with cerebral amyloid deposition
por: Lee, Dongjoon, et al.
Publicado: (2022) -
The clinical use of blood-test factors for Alzheimer’s disease: improving the prediction of cerebral amyloid deposition by the QPLEX(TM)Alz plus assay kit
por: Kim, Haeng Jun, et al.
Publicado: (2021) -
Low Serum Phosphorus Correlates with Cerebral Aβ Deposition in Cognitively Impaired Subjects: Results from the KBASE Study
por: Park, Jong-Chan, et al.
Publicado: (2017) -
Synergistic interaction between APOE and family history of Alzheimer’s disease on cerebral amyloid deposition and glucose metabolism
por: Yi, Dahyun, et al.
Publicado: (2018)